U.S. law firms Weil, Gotshal & Manges and Goodwin are taking lead advisory roles on the $1.45 billion acquisition of Cambridge-based biotech firm Kymab by French pharma giant Sanofi. 

Under the deal terms, Sanofi will pay $1.1 billion upfront and up to $350 million upon achievement of certain milestones, according to an announcement by the firms on Monday.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]